What If Sobriety Feels Impossible Because Your Brain Was Never Given a Fair Start?

People tell me things in clinical spaces that they don’t say anywhere else.

One of the things I hear most often — from people who want to ‘be better’, who genuinely want to change, who have tried more times than they can count — is some version of this:

“I don’t know who I am without it.”

Or:

“Sober, I don’t know who I am and can’t relate to anyone.”

Or, most honestly:

“I’m scared. Being sober means I’m alone.”

We tend to hear these statements as psychological. As evidence of attachment, of identity fusion, of the deep grooves that addiction carves into a life. And those dimensions are real — I am not dismissing them.

But I want to offer something that the recovery conversation rarely includes. Something that reframes the fear not as weakness, but as an accurate perception of a neurochemical reality that was set long before the first drink, the first hit, the first prescription … perhaps before the person was born!

What if the sober baseline feels unbearable because it was never a healthy baseline to begin with?

The Baseline That Was Never Stable

We assume that sobriety returns a person to their natural state. That underneath the substance use, there is a neurologically intact self waiting to be recovered.

For many people, that assumption is wrong — and science is beginning to explain why.

The mesolimbic dopamine system — the brain’s primary reward and motivation circuit — is not a fixed structure. It is shaped by experience, by stress, and critically, by chemical exposures during development. The dopamine signaling that governs how a person experiences pleasure, motivation, anticipation, and a felt sense of aliveness is built during windows of neurological formation that cannot be revisited.

Peer-reviewed research now documents that endocrine-disrupting chemicals — BPA, phthalates, PCBs, parabens, pesticides, compounds in everyday plastics and personal care products — directly alter the architecture of this system. Prenatal and neonatal exposure to BPA has been shown to enhance mesolimbic dopamine activity in ways that produce hyperreactivity, attentional dysregulation, and a measurably heightened sensitivity to drugs of abuse. Animal self-administration studies have tested this hypothesis directly: early EDC exposure increases the drive to seek and maintain substance use.

This is not theoretical. This is the fetal origins of vulnerability — biochemical individuality shaped before birth, before language, before any choice was ever made.

When the Substance Is Doing the Work the Brain Can’t

Here is what this means in lived experience.

If your dopaminergic baseline was chemically compromised during development, your unaltered neurological state may be characterized by a deficit that feels like flatness, disconnection, anhedonia — the inability to feel genuine pleasure or interest in ordinary life. Not depression exactly. More like a kind of muted existence. A world that doesn’t land, doesn’t register with the weight and color it seems to carry for other people.

Into that deficit, a psychoactive substance arrives and does something extraordinary: it floods the system with the neurochemical signal the brain has been starved of. Suddenly, there is color. There is warmth. There is a felt sense of being present in a life that matters.

The person isn’t getting high. They are, for the first time, feeling something close to regulated.

Of course, sobriety feels like a loss. Of course, it feels like returning to nothing. Because without the substance, they are returning to a neurological state that was never resourced to feel like enough — not because of who they are, but because of what was done to their developing neurochemistry by a chemical environment that no one warned them about.

When a person tells me they don’t know who they are without the substance, I believe them. The self they have known — the one that can engage, connect, feel motivated, experience pleasure — may have only existed in the presence of that neurochemical amplification. That is not a weakness. That is neuroscience.

The Hypothalamus and the Body That Can’t Settle

The appetitive state — the brain’s motivational drive toward reward-seeking — is regulated in large part by the hypothalamus. Two of its most powerful appetite-driving neuropeptides, AgRP and NPY, govern not just hunger for food but the broader biological drive to seek, to want, to pursue.

Research has documented that BPA directly stimulates these orexigenic neuropeptides. Environmental estrogens have been shown to alter hypothalamic neural development during critical windows, improperly programming the populations of neurons responsible for the felt experience of satiation — of having enough.

What this creates, at the level of lived experience, is a body and brain that cannot settle. A nervous system that reads ordinary life as insufficient and keeps driving toward more — more stimulation, more relief, more of whatever temporarily quiets the relentless signal that something is missing.

This is not a character flaw. This is a hypothalamus that was chemically taught never to register enough.

And it is the reason why telling someone to stop — to white-knuckle their way back to a baseline that was already impoverished — is not a treatment plan. It is an instruction to endure a deficit without any support for addressing what created the deficit in the first place.

The Identity Question Deserves a Better Answer

When someone tells me the idea of sobriety is terrifying because they don’t believe they can relate to the world without feeling like a different person, they are not being dramatic. They are describing a genuine discontinuity between their neurochemically amplified self and their neurochemically depleted one.

The recovery conversation tends to treat this as the addiction talking — as resistance, as denial, as the disease protecting itself. Sometimes that framing is useful. But it doesn’t account for the person whose underlying neurobiology was never given the conditions to build a stable, regulated baseline in the first place.

What these individuals need is not simply the removal of the substance. They need a systematic, individualized approach to rebuilding the neurological infrastructure that was never properly established — one that accounts for their biochemical individuality, their specific receptor sensitivities, and their hormonal and neuroendocrine terrain.

They need to know that the self they are afraid of losing was always more complex than the substance, and that the self waiting on the other side of genuine regulation — not white-knuckled abstinence, but actual neurological restoration — is someone worth staying for.

That conversation begins when we stop asking what is wrong with a person and start asking what happened to their biochemistry. When we bring the science of endocrine disruption, developmental neurotoxicology, and biochemical individuality into a space where the only framework on offer has been moral failing or disease management.

A Different Starting Question

What if the question isn’t: ‘Why can’t you just stop?’

What if the question is: ‘What would have to be true in your neurochemistry for this to make complete sense?’

Because when we start there, the shame falls away. The self-blame loses its grip. And the real work — the upstream, individualized, biochemically honest work — becomes possible.

The brain has not betrayed you. It has been adapting, as brains do, to conditions it was placed in without consent. The task is not to force it back to a baseline that was never resourced. The task is to build, perhaps for the first time, the neurological conditions for genuine regulation.

That is not a relapse prevention plan. That is a different understanding of what recovery could mean.

And it starts with being willing to ask a more honest question about where the baseline came from.

Tammy L. Davis is a Master Clinical Neuroaromatherapist, founder of Aromagenomics, and developer of the ANIS™ (Aromatic Neural Integrative System). She trains licensed healthcare professionals in evidence-based neuroaromatherapy and is the author of The Scent of Enough and a seven-book series titled: A Constituent-Based Guide to Essential Oils, with book 1 available now!

P.S. If this reframe is landing for you as a clinician — if you’ve sat with clients in exactly this place and felt the limits of the frameworks available to you — the ANIS™ Practitioner Intensive is where we build the clinical language and the individualized protocols to do this work with precision. The May workshop intensive is open. You can find the details here.

Key literature:

• Schug et al. (2015). Elucidating the Links Between Endocrine Disruptors and Neurodevelopment. Endocrinology, 156(6).

• Vassilopoulou et al. (2024). The Role of Endocrine Disruptors in Obesity. Int J Mol Sci, 25(1).

• PubMed PMID: 18555207 — Environmental neurotoxicants, dopaminergic system, and addiction vulnerability.

• SUNY Research Program: Addiction, Gender, and Endocrine Disruptors.